Need Help?

INSPIRE - Investigator-initiated Phase 2 Study of Pembrolizumab Immunological Response in Metastatic Solid Tumors

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001004873 Illumina HiSeq 2500 100
EGAD00001006562 Illumina HiSeq 2500 95
EGAD00001006563 Illumina HiSeq 2500 96
EGAD00001006564 Illumina HiSeq 2500 107
EGAD00001006569 186
Publications Citations
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).
J Immunother Cancer 7: 2019 72
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.
JNCI Cancer Spectr 5: 2021 None
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.
Nat Commun 12: 2021 5137